Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label spesolimab treatment in palmoplantar pustulosis
2020-000189-41Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spesolimab in Palmoplantar Pustular Psoriasis (PPPP), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events. Started May 2020; status: completed.
02
Drugs
spesolimab
03
Conditions
Palmoplantar Pustular Psoriasis (PPPP)
Beyond the preview
Go deeper on 2020-000189-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000189-41.